Skip to main content
Equibles
HAE logo

HAE · Haemonetics Corp · Metrics

Track HAE — free

Use HAE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HAE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$102.69 +1.63 (+1.61%) At close · Sep 11
S&P 400 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.67B
Shares
45.50M

HAE metrics

92 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$102.69
Market cap
$4.67B

Price action

20 metrics
Price change (1W)
-1.7%
Price change (30D)
+11.8%
Price change (3M)
+26.6%
Price change (6M)
+69.9%
Price change (YTD)
+26.1%
Price change (1Y)
+88.3%
Trailing year
Price change (5Y)
+49.8%
52-week high
$108.80
52-week low
$47.67
Change from 52-week high
-7.1%
Change from 52-week low
+112.0%
Annualized volatility
49.4%
Annualized volatility (3M)
43.5%
Beta
0.1
RSI (14D)
58.1
Price vs SMA 50
+13.1%
Price vs SMA 200
+38.2%
Avg volume (3M)
787,330
Relative volume
0.8
Average dollar volume
$67.99M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
45.50M

Valuation

12 metrics
P / E (TTM)
48.8
Trailing earnings · reciprocal yield 2.0%
PEG ratio
17.1
EV / revenue
4.1×
reciprocal yield 24.4%
EV / EBITDA
20.5×
reciprocal yield 4.9%
EV / EBIT
34.6×
reciprocal yield 2.9%
P / sales
3.4×
reciprocal yield 29.4%
P / book
5.5
reciprocal yield 18.2%
FCF yield
6.3%
TTM · current market cap
Buyback yield
—
P / FCF
15.8
reciprocal yield 6.3%
P / operating cash flow
14.0
reciprocal yield 7.1%
Earnings yield
2.1%

Historical valuation

8 metrics
P / E historical average (3Y)
30.2×
reciprocal yield 3.3%
P / E historical average (5Y)
44.3×
reciprocal yield 2.3%
EV / revenue historical average (3Y)
3.4×
reciprocal yield 29.4%
EV / revenue historical average (5Y)
3.7×
reciprocal yield 27.0%
EV / EBIT historical average (3Y)
24.8×
reciprocal yield 4.0%
EV / EBIT historical average (5Y)
34.3×
reciprocal yield 2.9%
EV / EBITDA historical average (3Y)
15.4×
reciprocal yield 6.5%
EV / EBITDA historical average (5Y)
18.0×
reciprocal yield 5.6%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
59.0%
Operating margin
11.9%
Trailing 12 months
Net margin
7.1%
Gross profit (TTM)
$798.14M
Operating profit (TTM)
$160.32M
Net income (TTM)
$96.29M
Trailing 12 months
Diluted EPS (TTM)
$2.07
FCF margin
21.5%
Effective tax rate
26.2%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$17.60

Growth

11 metrics
Revenue growth YoY
+5.6%
Year over year
Net income growth YoY
-3.0%
Revenue (TTM)
$1.35B
Trailing 12 months
EPS growth YoY
+2.9%
Shares change YoY
-5.5%
Year over year · fewer shares
Revenue CAGR (3Y)
+4.5%
Revenue CAGR (5Y)
+8.9%
EPS CAGR (3Y)
-2.9%
EPS CAGR (5Y)
+5.8%
FCF CAGR (3Y)
+47.2%
FCF CAGR (5Y)
+29.4%

Quality

14 metrics
Return on equity
11.5%
Return on assets
4.1%
Debt / equity
1.4
Current ratio
3.1
EBITDA (TTM)
$270.39M
Free cash flow (TTM)
$291.22M
Quick ratio
1.9
Interest coverage
—
Net debt / EBITDA
3.5
Return on invested capital
6.6%
Trailing 12 months
Net cash
−$950.77M
Latest balance sheet
Cash & equivalents
$223.38M
Total assets
$2.37B
Total debt
$1.17B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$328.15M
Capital expenditures (TTM)
$36.93M
R&D (TTM)
$59.70M
SG&A (TTM)
$450.64M
Stock compensation (TTM)
$33.83M
R&D / revenue
4.4%
Stock compensation / revenue
2.5%

Ownership (13F)

3 metrics
13F filers
331
13F filer change QoQ
+7
Institutional ownership
110.1%

Short interest

3 metrics
Short interest
6.3%
Latest settlement · 3.4 days to cover
Days to cover
3.4d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 313143 CUSIP 405024100 13F (30d) 135 filings 135 filers Visit website Investor relations